Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 11:36 PM
Ignite Modification Date:
2025-12-25 @ 9:25 PM
NCT ID:
NCT03222856
Pre Assignment Details:
Written informed consent. Females ≥18. ECOG status must be 0 or 1. Life expectancy ≥12 weeks. Patients have histologically and/or cytologically confirmed breast cancer. Radiologic evidence of inoperable lrMBC. HER2-negative breast cancer (by ISH or IHC) of 0,1+,2+. HR-positive BC with \>1% of tumor cells. Available tumor tissue for PD-L1 analysis.
Recruitment Details:
Between Dec 2017 and Oct 2018, a total of 44 patients with HR+ and HER2- MBC were enrolled at 11 sites. These patients were distributed into one arm and treated with pembrolizumab combinated with Eribulin.
Study:
NCT03222856
Study Brief:
Results Section:
NCT03222856